Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies

Objective This study was undertaken to compare toxicity and outcomes from cisplatin-based combination chemotherapy for black and white women with advanced /recurrent cervical cancer. Study Design Frequencies of grade 3 and 4 toxicities, response, and survival were compared by race using data from 3...

Full description

Saved in:
Bibliographic Details
Published in:American journal of obstetrics and gynecology 2008-11, Vol.199 (5), p.539.e1-539.e6
Main Authors: Plaxe, Steven C., MD, Brooks, Sandra E., MD, Tian, Chunquiao, MS, Bloss, Jeffrey D., MD, Moore, David H., MD, Long, Harry J., MD
Format: Article
Language:English
Subjects:
African Continental Ancestry Group
Antineoplastic Agents - toxicity
Antineoplastic Combined Chemotherapy Protocols - toxicity
Biological and medical sciences
cervical cancer
chemotherapy
Cisplatin - toxicity
Disease Progression
Drug Tolerance
European Continental Ancestry Group
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Leukopenia - chemically induced
Medical sciences
Middle Aged
Neutropenia - chemically induced
Obstetrics and Gynecology
race
Recurrence
Thrombocytopenia - chemically induced
Tumors
Uterine Cervical Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective This study was undertaken to compare toxicity and outcomes from cisplatin-based combination chemotherapy for black and white women with advanced /recurrent cervical cancer. Study Design Frequencies of grade 3 and 4 toxicities, response, and survival were compared by race using data from 3 Gynecologic Oncology Group studies. Results Black women experienced significantly less grade 3 and 4 neutropenia (63% vs 82%), leukopenia (58% vs 79%), thrombocytopenia (10% vs 23%), and adverse events of any nature (84% vs 93%) compared with white women. Black patients were not at increased risk of disease progression (adjusted relative risk, 1.11; 95% confidence interval, 0.88-1.38; P = .382) or death (adjusted relative risk, 1.02; 95% confidence interval, 0.82-1.26; P = .893). Conclusion Cisplatin-based chemotherapy delivered in a protocol setting for advanced/recurrent carcinoma of the cervix appears better tolerated by black women.
ISSN:0002-9378
1097-6868
DOI:10.1016/j.ajog.2008.04.038